{"title":"The Effects of Novel AMPK Activator on Human Vascular Endothelial Cells","authors":"Han‐Min Chen, Jiun‐Tsai Lin, Cheng-Yi Kuo, Chun-fang Huang","doi":"10.12720/JOMB.3.2.144-148","DOIUrl":null,"url":null,"abstract":"Adenosine 5'-monophosphate-activated protein kinase (AMPK) is a key regulator of cellular energy homeostasis and involved in modulating several important cellular mechanism including inflammation. Here we demonstrated that a novel AMPK activator, ENERGI-F704, dose-dependently activated AMPK in human umbilical vein endothelial cells (HUVECs). The pharmacological AMPK inhibitor, compound C, abolished the phosphorylation of threonine 172 residue on AMPK induced by ENERGI-F704. Importantly, ENERGI-F704 treatment did not affect HUVECs viability at the tested concentration. It was also observed that ENERGI-F704 significantly reduced the expression of inflammation cytokine, IL-6, in the high glucose cultured HUVECs during the long culture period. Furthermore, ENERGI-F704 suppressed the high glucose induced monocytotic adhesion to HUVECs. Collectively, our data demonstrated that ENERGI-F704 is of use in the application of attenuating the high glucose induced chronic inflammation in endothelial cells. ","PeriodicalId":437476,"journal":{"name":"Journal of medical and bioengineering","volume":"54 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of medical and bioengineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12720/JOMB.3.2.144-148","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Adenosine 5'-monophosphate-activated protein kinase (AMPK) is a key regulator of cellular energy homeostasis and involved in modulating several important cellular mechanism including inflammation. Here we demonstrated that a novel AMPK activator, ENERGI-F704, dose-dependently activated AMPK in human umbilical vein endothelial cells (HUVECs). The pharmacological AMPK inhibitor, compound C, abolished the phosphorylation of threonine 172 residue on AMPK induced by ENERGI-F704. Importantly, ENERGI-F704 treatment did not affect HUVECs viability at the tested concentration. It was also observed that ENERGI-F704 significantly reduced the expression of inflammation cytokine, IL-6, in the high glucose cultured HUVECs during the long culture period. Furthermore, ENERGI-F704 suppressed the high glucose induced monocytotic adhesion to HUVECs. Collectively, our data demonstrated that ENERGI-F704 is of use in the application of attenuating the high glucose induced chronic inflammation in endothelial cells.